Immediate-Type Hypersensitivity to Succinylated Corticosteroids

Annett Isabel Walker\textsuperscript{a} Helen-Caroline Räwer\textsuperscript{a} Wolfgang Sieber\textsuperscript{b} Bernhard Przybilla\textsuperscript{a}

\textsuperscript{a}Klinik und Poliklinik für Dermatologie und Allergologie, AllergieZENTRUM, Ludwig-Maximilians-Universität, München, und \textsuperscript{b}Abteilung für Pneumologie und Allergologie, Kreiskrankenhaus Wörth an der Donau, Wörth, Deutschland

Abstract

**Background:** Despite their frequent use, systemic corticosteroids have rarely elicited immediate-type reactions. **Objective:** We report two male patients, aged 26 and 70 years, respectively, with severe immediate-type hypersensitivity secondary to the administration of corticosteroids esterified with succinate. **Methods:** Skin tests, basophil activation tests and challenge tests were performed for diagnostic evaluation. **Results:** In both patients, immediate-type skin test reactions were found to methylprednisolone sodium hemisuccinate (MSH) and prednisolone sodium hemisuccinate (PSH). In contrast, nonsuccinylated corticosteroids (including methylprednisolone and prednisolone in one patient) yielded no test reactions. Basophils from one patient exhibited a stimulated expression of the activation marker CD63 upon in vitro incubation with PSH or hydrocortisone sodium succinate, but not with hydrocortisone. Skin tests and basophil activation tests were negative in controls. One patient was challenged with the incriminated drugs. He developed flush, conjunctivitis, tachycardia and dyspnea 2 min after injection of MSH, and dyspnea shortly after intravenous administration of PSH. Oral and intravenous challenge tests with nonsuccinylated corticosteroids were tolerated well by...
Introduction

Corticosteroids are rarely suspected as causative agents of immediate-type hypersensitivity as their anti-allergic properties would seem to contradict their capacity to induce such reactions. However, worsening of allergic symptoms during corticosteroid therapy may not always indicate treatment failure. Therefore, the possibility of corticosteroid hypersensitivity has to be considered.

Immediate-type reactions such as sneezing, angioedema, generalized urticaria, bronchospasm, hypotension or even anaphylactic shock have been observed after oral, intravenous, intramuscular, subcutaneous, or intra-articular administration of corticosteroids [1]. Approximately 100 cases of immediate-type hypersensitivity to corticosteroids have been reported [1, 4–13]. The pathomechanism of these reactions has remained unclear in most patients, but positive skin test reactions or specific IgE antibodies to the suspected elicitors were found in some patients [3–17]. Challenge tests were performed in just a few cases, and most of them were positive [5, 8, 14, 18–20].

We here report two patients with immediate-type reactions to corticosteroids whose test results indicate immediate-type allergy to the succinate moiety of succinylated corticosteroids to be the underlying pathomechanism of hypersensitivity.

Case Report

Patient 1

History

In 2000, a then 26-year-old male developed flush and dyspnea after being stung by a yellow jacket. He received an intravenous injection of prednisolone sodium hemisuccinate (PSH, Solu-Decortin® H), whereupon his symptoms worsened. In 2004, he again experienced a systemic reaction after a yellow jacket sting, and was treated with intravenous methylprednisolone sodium hemisuccinate (MSH, Urbason® soluble), clemastine fumarate (Tavegil®) and presumably dimethindene maleate (Fenistil®). He developed anaphylactic shock within 15 min after administration of these drugs. The patient recovered from both episodes without sequelae. Skin examination revealed no manifestations of mastocytosis; baseline serum tryptase concentration was 8.3 μg/l (95th percentile in normals, 11.4 μg/l).

Allergological Tests

Skin prick tests with three commercial injectable corticosteroid solutions, i.e. PSH 5 mg/ml (Solu-Decortin H), MSH 1.6 mg/ml (Urbason soluble) and hydrocortisone sodium succinate (HSS) 50 mg/ml (Hydrocortison rotemedica), induced positive reactions (wheal diameter 4 mm) after 20 min; in contrast, neither corticosteroids without a succinate moiety, nor other succinylated substances, or succinic acid itself (2.5 mg/ml; Sigma-Aldrich®, Munich, Germany) yielded positive skin prick test reactions (table 1). Histamine dihydrochloride (0.1%) served as positive control and elicited a positive reaction (wheal diameter 4 mm). There was no skin test reaction to physiological saline (negative control).

In five healthy volunteers, skin prick tests performed as described above with PSH, MSH and HSS were negative. In addition, skin prick tests with a standard series of common aeroallergens were performed in the patient, and revealed positive reactions (wheal diameter 3–6 mm) to numerous allergens. Assessment of patient’s serum with CAP-FEIA (Phadia, Freiburg, Germany) revealed specific IgE antibodies to yellow jacket (16.0 kU/l; CAP class 3) and bee venom (0.78 kU/l; CAP class 2), but no specific IgE antibodies to natural rubber latex. Total IgE was 241 kU/l (normal range <100 kU/l). A basophil activation test was performed using the Flow2 CAST system (Bühlmann Laboratories, Schönenbuch, Switzerland). Briefly, EDTA whole blood was incubated with prednisolone sodium phosphate, PSH and HSS at different concentrations as well as with formyl-methionyl-leucyl-phenylalanine (fMLP), which served as positive control, and stimulation buffer (negative control). A staining reagent containing monoclonal antibodies to human CD63 (activation marker on basophils) labeled with fluorescein isothiocyanate (anti-CD63–FITC) and to human chemokine receptor CCR3 (basophil marker) labeled with phycoerythrin (anti-CCR3–PE) was added. Cells were then analyzed by flow cytometry. The corticosteroids did not induce basophil activation in this test; the positive control yielded a stimulation of 18.15%.

To prove that PSH and MSH were the eliciting compounds in a single-blind manner, placebo-controlled challenge tests were performed. In accordance with current guidelines for drug provocation tests [21], incremental doses of PSH (1, 5, 10, 50, 100 mg) and MSH (2, 8, 15, 75 mg) were administered intravenously on different days at intervals of 90 min after placement of an intravenous line and under close monitoring in the intensive care unit [21, 22]. Shortly after administration of 100 mg PSH, the patient became dyspneic. Two minutes after injection of 75 mg MSH, he developed flush, conjunctivitis, tachycardia and dyspnea. In contrast, intravenous challenge tests with a succinate-free corticosteroid preparation (dexamethasone sodium phosphate, Dexta-ratiopharm®; maximum single dose: 40 mg), clemastine fumarate (Tavegil®; maximum single dose: 2 mg) and dimethindene maleate (Fenistil®; maximum single dose 4 mg) as well as oral challenges with betamethasone (Celestamine® N 0.5 liquidum; maximum single dose: 9 mg), doxylamine succinate (Sedaplus® Saft; maximum single dose 30 mg) and DL-α-tocopheryl acid succinate (Merz Spezial Dragees; maximum single dose: 10 mg) were tolerated well.
Yellow jacket venom immunotherapy was started. In addition, he was provided with an emergency kit containing betamethasone (Celestamine N 0.5 liquidum) and dimethindene maleate (Fenistil) for oral self-application, self-injectable adrenaline (Anapen®) and dexamethasone sodium phosphate (Dexa-ratiopharm) for intravenous injection by a physician in case of emergency.

Patient 2

History

A 70-year-old male patient had received PSH- and HSS-containing preparations intravenously because of acute hearing loss. He started to develop nausea and vomiting within seconds, and finally he lost consciousness. Emergency treatment including administration of adrenaline was performed, and he recovered without sequelae. Medical history included stenosis of the carotid artery, cardiovascular disease, hypertension and hyperuricemia. Skin examination was without pathological findings. Baseline serum tryptase concentration was 5.1 μg/l (95th percentile in normals: 11.4 μg/l).

Allergological Assessment

The patient presented 15 years after the reaction. Skin prick tests with 4 corticosteroids and succinic acid were negative (table 2). Intradermal tests were positive (wheat diameter 12 mm) for both PSH 0.5 mg/ml (Solu-Decortin H) and MSH 0.16 mg/ml (Urbason soluble) (wheat diameter 10 mm) whereas intradermal tests with HSS 0.5 mg/ml (Hydrocortison rotexmedica) and triamcinolone acetonide dipotassium phosphate 1 mg/ml (Volon® A soluble) yielded negative results. There was no skin test reac-
tion to intradermal physiological saline (negative control); histamine dihydrochloride (0.1%) yielded a strongly positive reaction (wheal diameter 8 mm) in the skin prick test.

Basophil activation tests with peripheral blood cells from the patient and from two nonatopic controls without a history of corticosteroid hypersensitivity were done using the Basotest\textsuperscript{®} (Orpe- gen Pharma, Heidelberg, Germany). In brief, heparinized whole blood was incubated with PSH, HSS and hydrocortisone at different concentrations as well as with fMLP (positive control) and Basotest stimulation buffer (negative control). Cells were double stained with a phycoerythrin-conjugated antibody to human IgE (identifying basophil granulocytes) and a fluorescein-conjugated antibody to glycoprotein gp53 (CD63) expressed on activated basophils. Cell characteristics were determined by flow cytometry. Analysis of the CD63 expression of the patient’s cells revealed significant positive responses to PSH and HSS at various concentrations but not to hydrocortisone (fig. 1). There was no activation of basophils from the two controls.

Because of the patient’s general condition and multiple concomitant diseases, he was not challenged with the incriminated drugs. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

**Discussion**

Skin prick or intradermal tests were positive to PSH and MSH in both patients – in patient 1 also to hydrocortisone sodium succinate. A challenge test was done in patient 1 with PSH and MSH and caused systemic symp- toms. Patient 2 was not challenged with the incriminated drugs because of his general condition and multiple concomitant diseases. Based on history and test results, we made a diagnosis of immediate-type hypersensitivity to certain corticosteroids, which, in view of positive skin and in vitro tests, probably has an immunological basis. Hypersensitivity was restricted to succinylated compounds as various corticosteroids without the succinate moiety were tolerated well.

To make corticosteroids water-soluble for intravenous application, they are often esterified with succinic acid, phosphoric acid or others, primarily at the C21 position [23]. Especially succinate esters seem to have a sensitizing potential [13]. Because of their low molecular weight, corticosteroids probably act as haptens [24–26].

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

**Discussion**

Skin prick or intradermal tests were positive to PSH and MSH in both patients – in patient 1 also to hydrocortisone sodium succinate. A challenge test was done in patient 1 with PSH and MSH and caused systemic symp- toms. Patient 2 was not challenged with the incriminated drugs because of his general condition and multiple concomitant diseases. Based on history and test results, we made a diagnosis of immediate-type hypersensitivity to certain corticosteroids, which, in view of positive skin and in vitro tests, probably has an immunological basis. Hypersensitivity was restricted to succinylated compounds as various corticosteroids without the succinate moiety were tolerated well.

To make corticosteroids water-soluble for intravenous application, they are often esterified with succinic acid, phosphoric acid or others, primarily at the C21 position [23]. Especially succinate esters seem to have a sensitizing potential [13]. Because of their low molecular weight, corticosteroids probably act as haptens [24–26].

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.

In patient 1, basophil activation tests using the Flow2 CAST system remained negative. In patient 2, expression of the activation marker CD63 was induced on basophils by hydrocortisone without the succinate moiety. However, intravenous challenges with dexamethasone disodium phosphate (Fortecortin\textsuperscript{®} Inject; maximum single dose 60 mg) and oral challenges with prednisolone (Decortin H; maximum single dose 50 mg), which are both succinate-free, were performed and well tolerated.
It has been claimed that immediate-type hypersensitivity reactions to corticosteroids could be triggered by nonimmunological mechanisms [17]. In some of the cases with negative prick tests, idiosyncrasy similar to reactions to acetylsalicylic acid was suspected [30]. In these cases, inhibition of cyclooxygenase is suggested to cause bronchospasm by blocking prostaglandin production which results in increased leukotriene production [30, 31]. Others suggested that some of these reactions, such as cardiovascular collapse, can be explained by rapid infusion of a considerable amount of corticosteroids, causing a decrease in cardiac output, secondary to α-adrenergic blockade and a negative inotropic effect [32, 33].

Asthma, nonsteroidal anti-inflammatory drug hypersensitivity and multiple high-dose applications of corticosteroids in the past have been considered to be risk factors for immediate-type hypersensitivity to corticosteroids [11], which may also be encountered more often in patients with atopic conditions or renal transplants [17]. However, these associations are vague, and current data do not support any unequivocal host factors that may predispose patients to corticosteroid hypersensitivity [17].

In recent years, immediate-type hypersensitivity reactions to succinylated corticosteroids have been described quite frequently [3, 4, 6, 7, 9, 11, 12, 14–16, 18, 24–26, 34–41] whereas such reactions to succinate-free corticosteroids seem to be less frequent [2, 5, 10, 19, 20, 42–44]. A number of patients had positive skin prick tests to the eliciting and related corticosteroids [11, 26, 45, 46]. Specific serum IgE antibodies to corticosteroids were demonstrated in a few cases [11, 24, 42].

In agreement with our results, 4 patients who experienced immediate-type reactions after administration of MSH, but who tolerated methylprednisolone without the succinate moiety well have been reported [15, 16, 18]. Koutsostathis and Vovolis [15], for example, reported 1 female patient who experienced an anaphylactic shock

Table 3. Synopsis of diagnostic results in published cases of systemic immediate-type hypersensitivity to succinylated corticosteroids

<table>
<thead>
<tr>
<th>Eliciting agent (as given by the original authors)</th>
<th>Skin prick test</th>
<th>Intradermal test</th>
<th>Challenge test with the eliciting agent</th>
<th>Other diagnostics</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylprednisolone hydrogen succinate (patient 1)</td>
<td>positive</td>
<td>ND</td>
<td>positive</td>
<td></td>
<td>[18]</td>
</tr>
<tr>
<td>Methylprednisolone hydrogen succinate (patient 2)</td>
<td>negative</td>
<td>positive</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate</td>
<td>negative</td>
<td>positive</td>
<td>ND</td>
<td></td>
<td>[16]</td>
</tr>
<tr>
<td>Methylprednisolone succinate</td>
<td>positive</td>
<td>positive</td>
<td>ND</td>
<td>demonstration of specific IgE antibodies to methylprednisolone succinate negative</td>
<td>[15]</td>
</tr>
<tr>
<td>Hydrocortisone succinate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td>[40]</td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate</td>
<td>ND</td>
<td>positive</td>
<td>ND</td>
<td></td>
<td>[7]</td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate</td>
<td>positive</td>
<td>positive</td>
<td>ND</td>
<td></td>
<td>[26]</td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate</td>
<td>ND</td>
<td>positive</td>
<td>ND</td>
<td></td>
<td>[25]</td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate</td>
<td>negative</td>
<td>positive</td>
<td>ND</td>
<td></td>
<td>[12]</td>
</tr>
<tr>
<td>Prednisolone sodium succinate</td>
<td>positive</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td>[4]</td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate</td>
<td>positive</td>
<td>positive</td>
<td>ND</td>
<td></td>
<td>[9]</td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate</td>
<td>positive</td>
<td>ND</td>
<td>ND</td>
<td>demonstration of specific IgE antibodies to methylprednisolone sodium succinate positive</td>
<td>[11]</td>
</tr>
<tr>
<td>Methylprednisolone sodium hemisuccinate</td>
<td>positive</td>
<td>positive</td>
<td>positive</td>
<td></td>
<td>[35]</td>
</tr>
<tr>
<td>Hydrocortisone sodium succinate</td>
<td>positive</td>
<td>positive</td>
<td>positive</td>
<td></td>
<td>[14]</td>
</tr>
<tr>
<td>Hydrocortisone sodium succinate</td>
<td>ND</td>
<td>positive</td>
<td>ND</td>
<td>demonstration of specific IgE antibodies to hydrocortisone sodium succinate negative</td>
<td>[3]</td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate</td>
<td>ND</td>
<td>positive</td>
<td>ND</td>
<td>scratch test positive</td>
<td>[17]</td>
</tr>
<tr>
<td>Hydrocortisone hemisuccinate</td>
<td>positive</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td>[38]</td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate</td>
<td>positive</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td>[6]</td>
</tr>
<tr>
<td>Prednisolone hemisuccinate</td>
<td>negative</td>
<td>(in 3/4 patients)</td>
<td>ND</td>
<td>demonstration of specific IgE antibodies to prednisolone hemisuccinate negative</td>
<td>[39]</td>
</tr>
</tbody>
</table>

ND = Not done.
after receiving MPS. Both, skin prick and intradermal tests were positive for MPS and hydrocortisone succinate. Koutsostathis and Vovolis challenged the patients only with nonsuccinylated corticosteroids. Challenge tests with succinylated corticosteroids (e.g. MPS) and other succinylated noncorticosteroid compounds were not performed [15]. In addition, we performed a basophil activation test. Besides our patients, there have been other cases related to this topic (table 3). However, it is not yet known how often corticosteroid hypersensitivity is restricted to succinylated compounds as it seems that the type of esterification has not always been considered. Immediate-type hypersensitivity to succinate salts as such has not been reported so far [4], nor have we found any reactions to succinic acid or other compounds than corticosteroids bearing the succinate moiety in patient 1. However, though the succinate fraction was comparable in doxylamine succinate (15.1 mg succinate per 50 mg), MSH (12.4 mg succinate per 50 mg) and PSH (12.8 mg succinate per 50 mg), the maximum allowed daily dose of doxylamine succinate was 50 mg whereas the administered doses of MSH or PSH were 100 or 166 mg, respectively. Also, in contrast to intravenous challenge tests with succinylated corticosteroids, oral challenge tests were performed with succinylated noncorticosteroid compounds.

Currently, anaphylactic reactions to other succinylated noncorticosteroid compounds in patients reporting immediate-type hypersensitivity to succinylated corticosteroids cannot be completely excluded. Though a challenge test with doxylamine succinate was well tolerated by one of our patients; it was just an oral challenge test with a low dose. Challenge tests with injectable succinylated noncorticosteroid compounds, in particular (e.g. gelatine polysuccinate), were not performed. Further studies have to clearly unravel this question.

In summary, it is important to be aware of the possibility of immediate hypersensitivity to corticosteroids in order to select treatment accordingly. Adequate allergological diagnosis is necessary in such patients not only to identify the culprit compound, but also to find a suitable corticosteroid for future intravenous treatment. Furthermore, such tolerated corticosteroids should be included in the patient’s emergency kit.

Acknowledgments

We thank M. Rolle, S. Gassner and A. Versec for skilled technical assistance.

References
